Geneviève Amaral

Geneviève Amaral

Auto-generated profile, based on publicly available information

Geneviève Amaral

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
GAGeneviève Amaral
Geneviève Amaral
VGVijay J. Gadkar
Vijay J. Gadkar
AAAbdulrahman Almodahka
Abdulrahman Almodahka
DGDavid Goldfarb
David Goldfarb
RPRyan Penny
Ryan Penny
LLLynne Li
Lynne Li
In Canada, Group A streptococcal (GAS) pneumonia is a severe invasive GAS (iGAS) condition reportable to public health for consideration of chemoprophylaxis for close contacts. It is often complicated by parapneumonic effusion. Sterile site culture from pleural fluid is the diagnostic gold standard but is insensitive, particularly given that many patients will have received antibiotics prior to sample collection. Xpert Xpress Strep A (Cepheid, Sunnyvale, CA) is a quantitative real-time (qPCR) assay targeting the speB gene designed to rapidly detect Streptococcus pyogenes from throat swabs. We evaluated its performance compared to bacterial culture for pediatric pleural fluids. A convenience sample of 36 specimens (21 positive, 15 negative) obtained January 2023 to April 2025 was included. Results were compared to a composite reference standard consisting of positive culture and a laboratory-developed (LD) qPCR targeting the spy1258 gene. Limit of detection (LoD) for LD qPCR was determined by testing a dilution series of negative pleural fluids spiked with a predefined concentration (copies/mL) of S. pyogenes ATCC 19615 and using 95% hit rate analysis for Xpert. All 21 positive samples tested (100%) were detected by Xpert and the composite reference standard, while only 8/21 (38%) were culture positive. Xpert demonstrated 100% positive percent agreement, negative percent agreement, and overall categorical agreement (ĸ = 1) with the composite reference standard and individual LD qPCR. There was 64% categorical agreement between Xpert and culture alone (ĸ = 0.3). Xpert was more sensitive for detecting S. pyogenes than culture from pleural fluid. Faster turnaround time shortened the window to optimal therapy, supporting its diagnostic utility. IMPORTANCE: Group A streptococcal (GAS) pneumonia, a predominant pathogen in pediatric complicated pneumonia and a severe form of invasive GAS infection, requires prompt diagnosis, both for clinical patient management and identification of close contacts for public health evaluation. Pleural effusion is a common complication. Recovery of GAS from a sterile site like pleural fluid is a key criterion to categorize disease as invasive. However, microbiological yield is often low and may be improved by applying molecular diagnostic techniques. In our study, we demonstrate the utility of Xpert Xpress Strep A for Cepheid GeneXpert for rapid detection of GAS in pediatric pleural fluids. We demonstrated excellent sensitivity with Xpert detecting all 21/21 (100%) positive specimens, compared to culture alone, which was only positive for 8/21 (38%).

29 July 2025 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Open access
GAGeneviève Amaral
Geneviève Amaral
CLCalvin Ka-Fung Lo
Calvin Ka-Fung Lo
GRGordon Ritchie
Gordon Ritchie
JBJennifer Bilawka
Jennifer Bilawka
CLChristopher Lowe
Christopher Lowe
ASAleksandra Stefanovic
Aleksandra Stefanovic
Timely identification of extended-spectrum beta-lactamase (ESBL)-producing bacteria supports early antimicrobial optimization, especially for patients with invasive infections. NG-Test® CTX-M MULTI (CTX-M LFA) is a rapid immunochromatographic assay for detection of Cefotaximase-Munich (CTX-M)-type ESBL. We evaluated its performance against existing molecular platforms. A sampling of archived Gram-negative bacteria (including Enterobacterales and non-fermenters) was included in the study. All isolates underwent testing for CTX-M ESBL by CTX-M LFA. CTX-M LFA results were compared to results from molecular methods, laboratory-developed (LD)-PCR (2013-2019) or BCID2 (2022-2023). Discordances were resolved with a combination of ESBL phenotypic testing and an alternative PCR platform, or whole-genome sequencing. Seventy-eight isolates were included in the study, all of which underwent CTX-M LFA and molecular testing (n = 47 by LD-PCR, n = 31 by BCID2). Post-discordance analysis showed positive percent agreement of 89.7 % (95 %CI 71.5-97.2 %), negative percent agreement 100 % (95 %CI 90.9-100 %) and overall categorical agreement 96.2 %, κ=0.92 (95 %CI 88.4-99.0 %). One E. coli was negative by CTX-M LFA but positive for blaCTX-M by BCID2. Whole-genome sequencing identified a non-functional blaCTX-M-27 gene with adenine insertion at position 70 in codon 24, causing a frameshift mutation resulting in a premature stop codon (codon 58). CTX-M LFA improved performance in comparison with molecular methods by accurately identifying an isolate with a prematurely truncated protein as a true-negative for CTX-M. This highlights potential limitations of molecular-based resistance detection. CTX-M LFA was simple to perform and yielded results within 15 minutes.

1 April 2026 in Access Microbiology
Verified
Journal Article
Open access
CLCalvin Ka-Fung Lo
Calvin Ka-Fung Lo
AAAhmad Aloufi
Ahmad Aloufi
GAGeneviève Amaral
Geneviève Amaral
HHHasan Hamze
Hasan Hamze
SMStephanie May
Stephanie May
VYVictor Tsun Ho Yuen
Victor Tsun Ho Yuen
Introduction. Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing MIC distributions for ceftriaxone, cefepime, piperacillin–tazobactam and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods. MIC data for AmpC isolates between November 2019 and October 2024 were retrieved (BD EpiCenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g. respiratory and wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2a-1). Descriptive statistics were computed and compared between moderate-risk AmpC (MRAC) inducers versus low-risk AmpC (LRAC) inducers. Results. A total of 5,631 isolates were analysed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin–tazobactam, cefepime and meropenem were 82.0%, 87.0%, 95.4% and 98.7%, respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin–tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC 90 for cefepime was 1 µg ml −1 for all species except Enterobacter cloacae (MIC 90 4 µg ml −1 ). Conclusion. Between 2019 and 2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.

16 June 2025 in Clinical Microbiology Newsletter
Verified
Journal Article
Open access
GAGeneviève Amaral
Geneviève Amaral
CLChristopher Lowe
Christopher Lowe
GRGordon Ritchie
Gordon Ritchie
CBConor Broderick
Conor Broderick
MPMichael Payne
Michael Payne
MRMarc G. Romney
Marc G. Romney

30 September 2025
Verified
Preprint
Open access
CLCalvin Ka-Fung Lo
Calvin Ka-Fung Lo
AAAhmad Aloufi
Ahmad Aloufi
GAGeneviève Amaral
Geneviève Amaral
HHHasan Hamze
Hasan Hamze
SMStephanie May
Stephanie May
VYVictor Tsun Ho Yuen
Victor Tsun Ho Yuen
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,809 isolates were analyzed, with 3,646 (62.8%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 81.6%, 87.4%, 95.5%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 91.1%) and piperacillin-tazobactam (81.5% versus 97.3%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.5% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.

11 March 2026
Verified
Preprint
Open access
CLCalvin Ka-Fung Lo
Calvin Ka-Fung Lo
AAAhmad Aloufi
Ahmad Aloufi
GAGeneviève Amaral
Geneviève Amaral
HHHasan Hamze
Hasan Hamze
SMStephanie May
Stephanie May
VYVictor Tsun Ho Yuen
Victor Tsun Ho Yuen
Introduction: Existing literature supports using cefepime as a carbapenem-sparing agent to treat AmpC-producing Enterobacterales infections. To characterize existing susceptibility trends, we conducted a 5-year retrospective study assessing minimum inhibitory concentration (MIC) distributions for ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem across Vancouver Island Health Authority (Vancouver Island, British Columbia, Canada). Methods: MIC data for AmpC isolates between November 2019 to October 2024 were retrieved (BD Epicenter™). Blood cultures, invasive specimens, urine and miscellaneous samples (e.g., respiratory, wounds) were included; we excluded surveillance specimens. MIC values were interpreted based upon CLSI M100-E34 breakpoints (Table 2A-1). Descriptive statistics were computed and compared between moderate-risk AmpC inducers (MRAC) versus low-risk AmpC inducers (LRAC). Results: 5,631 isolates were analyzed, with 3,778 (67.1%) identified as MRAC. Across all organisms, susceptibility rates for ceftriaxone, piperacillin-tazobactam, cefepime, and meropenem were 82.0%, 87.0%, 95.4%, and 98.7% respectively. Compared to LRAC, MRAC organisms demonstrated lower susceptibility to ceftriaxone (76.0% versus 94.2%) and piperacillin-tazobactam (81.3% versus 98.6%). Cefepime and meropenem demonstrated similar susceptibility rates between LRAC and MRAC. MIC90 for cefepime was 1 µg/ml for all species except E. cloacae (MIC90 4µg/ml). Conclusion: Between 2019-2024, 95.4% of our isolates demonstrated susceptibility to cefepime within our local health authority. Further research will correlate patient outcomes and establish MIC thresholds to guide routine testing and clinical use of cefepime.